DCF Advisers’s Royalty Pharma RPRX Stock Holding History

DCF Advisers’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1,000	Closed	-$28.3K	–	109
2024 Q3	$28.3K	Buy	+1,000	New	+$27.7K	0.01%	95

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DCF Advisers's RPRX Position: Q4 2024 in Review

DCF Advisers sold out of Royalty Pharma (RPRX) in Q4 2024, closing a stake of 15,000 shares — an estimated $424K sold.

DCF Advisers first reported a position in RPRX in Q3 2024 and held it in 1 quarter. The position peaked at $424K in Q3 2024. 416 funds tracked by Wall St. Rank hold RPRX as of Q4 2024.

DCF Advisers reported no remaining Royalty Pharma position as of Q4 2024 after selling out during the quarter.
DCF Advisers sold 15,000 Royalty Pharma shares in Q4 2024, an estimated $424K.
DCF Advisers first reported a position in Royalty Pharma in Q3 2024 and held it in 1 quarter.
DCF Advisers's Royalty Pharma position peaked at $424K in Q3 2024.
416 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2024.

Based on DCF Advisers's 13F filing for Q4 2024, filed 11 Feb 2025.